Xconomy: Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship’s Latest Microbiome Startup
Summary
It’s putting some more of that cash to work as of this morning, unveiling a startup, Kaleido Biosciences, that has been incubated within its walls for two years and is run by a prominent former Boston-area CEO.Mike Bonney (pictured), the former head of antibiotics developer Cubist and until late last year a Third Rock Ventures partner, has been named the CEO and chairman of the Cambridge, MA, startup.The firm, which according to an SEC filing last week is in the process of raising a new $500 million fund, previously formed Seres Therapeutics (NASDAQ: MCRB).Specifically, the drugs are meant to “enhance or protect” the microbiome’s ability to chew up nutrients and use chemical signals to talk with other parts of the body.“I truly believe Kaleido – with its deep scientific understanding, R&D engine and pipeline – has the potential to transform the way we treat and prevent disease,” said Bonney in a prepared statement.